11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million verdict ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.

A Delaware judge ordered Alexion Pharmaceuticals Inc. to pay $181 million in damages, plus interest, to former shareholders of Syntimmune Inc., which Alexion bought in a 2018 transaction that provided ...

A Delaware judge ordered Alexion Pharmaceuticals Inc. to pay $181 million in damages, plus interest, to former investors in Syntimmune Inc., which it bought in a 2018 transaction that provided for ...

Why Salesforce plans to buy Informatica in an $8 billion AI deal The software giant faces ‘growing pressure to increase adoption of Agentforce,’ its agentic AI offering, according to an analyst.

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published 2 hours ago • Updated 46 mins ago BOOKMARKER ...

AstraZeneca’s unit Alexion has partnered with Pangaea Data to fund the startup’s development of an AI tool for detecting HPP. Skip to site menu Skip to page content. MD. Menu. ... Private equity deals ...